Is CGTX or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% Palisade Bio N/A -33.47% -31.79%

Does the media prefer CGTX or PALI?

In the previous week, Cognition Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Cognition Therapeutics and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.63 beat Cognition Therapeutics' score of 1.40 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CGTX or IKT more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% Inhibikase Therapeutics N/A -42.80% -40.58%

Does the media favor VNDA or CGTX?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Cognition Therapeutics and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Cognition Therapeutics' score of 1.40 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TTRX or CGTX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A

Is TTRX or CGTX more profitable?

Cognition Therapeutics' return on equity of -50.17% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% Cognition Therapeutics N/A -50.17% -40.22%

Does the media refer more to TTRX or CGTX?

In the previous week, Turn Therapeutics had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 5 mentions for Turn Therapeutics and 4 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.40 beat Turn Therapeutics' score of 0.42 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRN or CGTX?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for Cognition Therapeutics and 2 mentions for Amarin. Cognition Therapeutics' average media sentiment score of 1.40 beat Amarin's score of 0.54 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cognition Therapeutics (CGTX) Competitors

$0.98 +0.00 (+0.32%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.98 +0.00 (+0.12%)

As of 09/11/2026 07:55 PM Eastern

Compare

CGTX vs. PALI, IKT, VNDA, TTRX, and AMRN

Should you buy Cognition Therapeutics stock or one of its competitors? Cognition Therapeutics's main competitors and comparable companies include Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Turn Therapeutics (TTRX), and Amarin (AMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cognition Therapeutics compare to Palisade Bio?

Cognition Therapeutics (NASDAQ:CGTX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Palisade Bio has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Palisade Bio	$250K	1,435.98	-$16.78M	-$0.48	N/A

Cognition Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 4 mentions for Cognition Therapeutics and 3 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 1.63 beat Cognition Therapeutics' score of 1.40 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cognition Therapeutics currently has a consensus price target of $3.33, indicating a potential upside of 239.17%. Palisade Bio has a consensus price target of $9.00, indicating a potential upside of 336.89%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Palisade Bio's return on equity of -33.47% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Palisade Bio	N/A	-33.47%	-31.79%

Summary

Palisade Bio beats Cognition Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Cognition Therapeutics has higher earnings, but lower revenue than Inhibikase Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Inhibikase Therapeutics	$260K	1,255.86	-$48.26M	-$0.43	N/A

Inhibikase Therapeutics' return on equity of -42.80% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cognition Therapeutics currently has a consensus target price of $3.33, indicating a potential upside of 239.17%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 130.77%. Given Cognition Therapeutics' higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Cognition Therapeutics had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 4 mentions for Cognition Therapeutics and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Cognition Therapeutics' score of 1.40 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Inhibikase Therapeutics	Very Positive

Cognition Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Summary

Cognition Therapeutics beats Inhibikase Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Cognition Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Cognition Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.42	-$220.47M	-$4.63	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Vanda Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 2 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 4 mentions for Cognition Therapeutics and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.61 beat Cognition Therapeutics' score of 1.40 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 169.16%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 239.17%. Given Cognition Therapeutics' higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Vanda Pharmaceuticals and Cognition Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Cognition Therapeutics' return on equity of -50.17% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

In the previous week, Turn Therapeutics had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 5 mentions for Turn Therapeutics and 4 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.40 beat Turn Therapeutics' score of 0.42 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics presently has a consensus target price of $8.00, indicating a potential downside of 36.96%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 239.17%. Given Cognition Therapeutics' higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

43.4% of Cognition Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Cognition Therapeutics beats Turn Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Cognition Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Amarin has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Cognition Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.36	-$38.80M	-$0.99	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

In the previous week, Cognition Therapeutics had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for Cognition Therapeutics and 2 mentions for Amarin. Cognition Therapeutics' average media sentiment score of 1.40 beat Amarin's score of 0.54 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Amarin shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cognition Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Amarin presently has a consensus price target of $13.00, indicating a potential downside of 5.80%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 239.17%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats Amarin on 12 of the 15 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$93.46M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-5.78	656.81	214.39	20.85
Price / Sales	N/A	756.96	633.80	90.72
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	2.52	10.39	10.33	6.21
Net Income	-$23.49M	$2.85B	$3.50B	$358.54M
7 Day Performance	-4.58%	-3.61%	-3.32%	-2.35%
1 Month Performance	-5.50%	0.72%	-0.53%	-3.23%
1 Year Performance	-54.71%	3.61%	23.51%	8.79%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	2.4439 of 5 stars	$0.98 +0.3%	$3.33 +239.2%	-54.7%	$93.46M	N/A	N/A	20	Positive News
PALI Palisade Bio	3.1216 of 5 stars	$2.09 +2.0%	$9.00 +330.6%	+244.5%	$364.23M	$250K	N/A	10	Positive News
IKT Inhibikase Therapeutics	2.2959 of 5 stars	$2.50 -0.8%	$5.40 +116.0%	+50.0%	$348.84M	$260K	N/A	6
VNDA Vanda Pharmaceuticals	3.0217 of 5 stars	$5.43 +1.7%	$13.70 +152.3%	+12.9%	$328.31M	$215.72M	N/A	290
TTRX Turn Therapeutics	1.5145 of 5 stars	$9.80 -2.7%	$8.00 -18.4%	N/A	$291.92M	N/A	N/A	2	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. PALI, IKT, VNDA, TTRX, and AMRN

How does Cognition Therapeutics compare to Palisade Bio?

Summary

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Summary

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Cognition Therapeutics compare to Turn Therapeutics?

Summary

How does Cognition Therapeutics compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. PALI, IKT, VNDA, TTRX, and AMRN

How does Cognition Therapeutics compare to Palisade Bio?

Which has stronger earnings and valuation, CGTX or PALI?

Which has more risk and volatility, CGTX or PALI?

Does the media prefer CGTX or PALI?

Do analysts recommend CGTX or PALI?

Do institutionals & insiders believe in CGTX or PALI?

Is CGTX or PALI more profitable?

Summary

How does Cognition Therapeutics compare to Inhibikase Therapeutics?

Which has stronger earnings and valuation, CGTX or IKT?

Is CGTX or IKT more profitable?

Do institutionals and insiders believe in CGTX or IKT?

Do analysts recommend CGTX or IKT?

Does the media refer more to CGTX or IKT?

Which has more risk & volatility, CGTX or IKT?

Summary

How does Cognition Therapeutics compare to Vanda Pharmaceuticals?

Is VNDA or CGTX more profitable?

Which has preferable earnings & valuation, VNDA or CGTX?

Which has more volatility & risk, VNDA or CGTX?

Does the media favor VNDA or CGTX?

Do analysts recommend VNDA or CGTX?

Do insiders and institutionals believe in VNDA or CGTX?

Summary

How does Cognition Therapeutics compare to Turn Therapeutics?

Is TTRX or CGTX more profitable?

Which has preferable valuation and earnings, TTRX or CGTX?

Does the media refer more to TTRX or CGTX?

Do analysts rate TTRX or CGTX?

Do insiders & institutionals believe in TTRX or CGTX?

Summary

How does Cognition Therapeutics compare to Amarin?

Which has more risk & volatility, AMRN or CGTX?

Which has better earnings and valuation, AMRN or CGTX?

Does the media favor AMRN or CGTX?

Do institutionals and insiders believe in AMRN or CGTX?

Is AMRN or CGTX more profitable?

Do analysts recommend AMRN or CGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools